Hepatic progenitor cells in liver cancers from Asian children

Liver International

Volumn 30, Issue 1, 2010, Pages 102-111

  Ward, Stephen C ^a   Thung, Swan N ^a   Lim, Kiat Hon ^a   Tran, Tung Thanh ^b   Hong, Thi Khang Bui ^b   Le Hoang, Phuc ^b   Jang, Ja June ^c   Park, Young Nyun ^d   Abe, Kenji ^e  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Children's Hospital No 1   (Viet Nam)

^c Seoul National University College of Medicine   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

^e NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

CK19; EpCAM; Hepatic progenitor cells; Hepatic stem cells; Hepatoblastoma; Paediatric hepatocellular carcinoma

Indexed keywords

ANTIBODY; EOSIN; EPITHELIAL CELL ADHESION MOLECULE; HEMATOXYLIN; K19 ANTIBODY; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS RNA;

ADOLESCENT; ARTICLE; ASIAN; CHILD; CLINICAL ARTICLE; FEMALE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATOBLASTOMA; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFANT; LIVER CANCER; LIVER CELL; LIVER CELL CARCINOMA; MALE; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; SCHOOL CHILD; STEM CELL; TUMOR CLASSIFICATION; TUMOR DIFFERENTIATION;

ADOLESCENT; ANTIGENS, NEOPLASM; CARCINOMA, HEPATOCELLULAR; CELL ADHESION MOLECULES; CHILD; CHILD, PRESCHOOL; DNA, VIRAL; FEMALE; HEPACIVIRUS; HEPATITIS B VIRUS; HEPATOBLASTOMA; HEPATOCYTES; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; KERATIN-19; LIVER NEOPLASMS; MALE; PROTO-ONCOGENE PROTEINS C-KIT; REPRODUCIBILITY OF RESULTS; RNA, VIRAL; STEM CELLS; TUMOR MARKERS, BIOLOGICAL;

EID: 73449134462     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2009.02126.x     Document Type: Article

References (57)

1. Meyers R.L. Tumors of the liver in children. Surg Oncol 2007; 16: 195-203.
2. Weinberg AG, Finegold MJ. Primary hepatic tumors in childhood. In: Finegold MJ, ed. Pathology of neoplasia in children and adolescents. Philadelphia, PA: W. B. Saunders, 1986; 333-65.
3. Isaacs H Jr Fetal and neonatal hepatic tumors. J Pediatr Surg 2007; 42: 1797-803.
4. Spector LG, Johnson KJ, Soler JT, Puumala S.E. Perinatal risk factors for hepatoblastoma. Br J Cancer 2008; 98: 1570-3.
5. Davies JQ, de la Hall PM, Kaschula RO, et al. Hepatoblastoma-evolution of management, outcome and significance of histology of the resected tumor. A 30-year experience with 41 cases. J Pediatr Surg 2004; 39: 1321-7.
6. Finegold MJ, Egler RA, Goss JA, et al. Liver tumors: pediatric population. Liver Transpl 2008; 14: 1545-56.
7. Schnater JM, Aronson DC, Plaschkes J, et al. Surgical view of the treatment of patients with hepatoblastoma: results from the first prospective trial of the International Society of Pediatric Oncology Liver Tumor Study Group. Cancer 2002; 94: 1111-20.
8. Jaskiewicz K, Banach L, Izycka E. Hepatocellular carcinoma in young patients: histology, cellular differentiation, HBV infection and oncoprotein p53. Anticancer Res 1995; 15: 2723-5.
9. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liv Dis 1999; 19: 271-85.
10. Kew M.C. Epidemiology of hepatocellular carcinoma. Toxicology 2002; 181-182: 35-8.
11. Moore SW, Davidson A, Hadley GP, et al. Malignant liver tumors in South African children: a national audit. World J Surg 2008; 32: 1389-95.
12. Ishak KG, Goodman ZD, Stocker J.T. Hepatoblastoma and Hepatocellular Carcinoma. In: Tumors of the Liver and Intrahepatic Bile Ducts. Washington, DC: Armed Forces Institute of Pathology, 2001; 159-83 and 199-230.
13. Roskams T, Vos RD, Eyken PV, et al. Hepatic OV-6 expression in human liver disease and rat experiments evidence for hepatic progenitor cells in man. J Hepatol 1998; 29: 455-63.
14. Sell S, Leffert H.L. Liver cancer stem cells. J Clin Oncol 2008; 26: 2800-5.
15. Theise ND, Yao JL, Harada K, et al. Hepatic "stem cell" malignancies in adults: four cases. Histopathology 2003; 43: 263-71.
16. Komuta M, Spee B, Van der Borght S, et al. Clinicopathological study on cholangiocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology 2008; 47: 1544-56.
17. Theise ND, Saxena R, Portmann BC, et al. The canals of Hering and hepatic stem cells in humans. Hepatology 1999; 30: 1425-33.
18. Kim JW, Ye Q, Forgues M, et al. Cancer-associated molecular signature in the tissue samples of patients with cirrhosis. Hepatology 2004; 39: 518-27.
19. Ma S, Chan KW, Hu L, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007; 132: 2542-56.
20. Mao L, Qiu YD, Fang S, et al. Liver progenitor cells activated after 30% small-for-size liver transplantation in rats: a preliminary study. Transplant Proc 2008; 40: 1635-40.
21. Durnez A, Verslype C, Nevens F, et al. The clinicopathological and prognostic relevance of cytokeratin7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology 2006; 49: 138-51.
22. Yang XR, Xu Y, Shi GM, et al. Cytokeratin 10 and cytokeratin 19: predictive markers for poor prognosis in HCC patients after curative resection. Clin Cancer Res 2008; 14: 3850-9.
23. Zhuang PY, Zhang JB, Zhu XD, et al. Two pathologic types of hepatocellular carcinoma with lymphnode metastasis with distinct prognosis on the basis of CK19 expression in tumor. Cancer 2008; 112: 2740-8.
24. Trzpis M, McLaughlin PMJ, de Leij LMFH, Harmsen M.C. Epithelial cell adhesion molecule. More than a carcinoma marker and adhesion molecule. Am J Pathol 2007; 171: 386-95.
25. Yamashita T, Forgues M,Wang W, et al. EpCAM and alphafetoprotein expression defines novel prognostic types of H.C.C. Cancer Res 2008; 68: 1451-61.
26. Ruck P, Xiao JC, Pietsch T, Kaiserling E. Hepatic stem cells in the human liver. Histopathology 1996; 29: 590-2.
27. Ruck P, Xiao JC, Pietsch T, Von Schweinitz D, Kaiserling E. Hepatic stem-like cells in hepatoblastoma: expression of cytokeratin 7, albumin and oval cell associated antigens detected by OV-1 and OV-6. Histopathology 1997; 31: 324-9.
28. Ruck P, Wichert G, Handgretinger R, Kaiserling E. Ep-CAM in malignant liver tumours. J Pathol 2000; 191: 102-3.
29. Badve S, Logdberg L, Lal A, et al. Small cells in hepatoblastoma lack "oval" cell phenotype. Mod Pathol 2003; 16: 930-6.
30. Fiegel HC, Gluer S, Roth B, et al. Stem-like cells in human hepatoblastoma. J Histochem Cytochem 2004; 52: 1495-501.
31. Nguyen VT, Law MG, Dore G.J. An enormous hepatitis B virus-related liver disease burden projected in Vietnam by 2025. Liver Int 2008; 28: 525-31.
32. Lee DH, Kim JH, Nam JJ, Kim HR, Shin H.R. Epidemiological findings of hepatitis B infection based on 1998 National Health and Nutrition Survey in Korea. J Korean Med Sci 2002; 17: 457-62.
33. Finegold M.J. Tumors of the Liver. Semin Liver Dis 1994; 14: 270-81.
34. Abe K, Edamoto Y, Park YN, et al. In situ detection of hepatitis B, C, and G virus nucleic acids in human hepatocellular carcinoma tissues from different geographic regions. Hepatology 1998; 28: 568-72.
35. Ishimura M, Ohga S, Nagatoshi Y, et al. Malignant hepatic tumor occurring 10 years after a histocompatible sibling donor bone marrow transplantation for severe apalastic anemia. Pediatr Transpl 2007; 11: 945-9.
36. Inagaki M, Yagi T, Urushihara N, et al. Successfully resected hepatoblastoma in a young adult with chronic hepatitis B: report of a case. Eur J Gastroenterol Hepatol 2001; 13: 981-4.
37. Gerber MA, Thung SN, Shen S, et al. Phenotypic characterization of hepatic proliferation: antigen expression by proliferating epithelial cells in fetal liver, massive hepatic necrosis, and nodular transformation of the liver. Am J Pathol 1983; 110: 70-4.
38. Sell S, Dunsford H. Evidence for the stem cell origin of hepatocellular carcinoma and cholangiocarcinoma. Am J Pathol 1989; 134: 1347-63.
39. Farber E. Ethionine carcinogenesis. Adv Cancer Res 1963; 7: 383-474.
40. Roskams TA, Theise ND, Balabaud C, et al. Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology 2004; 39: 1739-45.
41. Haque S, Haruna Y, Nalesnik MA, et al. Identification of bipotential progenitor cells in human liver regeneration. Lab Invest 1996; 75: 699-705.
42. Robrechts C, De Vos R, Van den Heuvel M, et al. Primary liver tumours of intermediate (hepatocyte-bile duct cell) phenotype: a progenitor cell tumour? Liver 1998; 18: 288-93.
43. Lee JS, Heo J, Libbrecht L, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006; 12: 410-6.
44. Villanueva A, Newell P, Chiang DY, et al. Molecular and clinical characterization of hepatocellular carcinoma with progenitor cell markers. 59th Annual Meeting of the American Association for the Study of Liver Diseases; 2008 October 31-November 4; San Francisco, C.A. Alexandria (VA): American Association for the Study of Liver Diseases; 2008. Hepatology 48 (Suppl.), 361A-2A.
45. Prokurat A, Kluge P, Kosciesza A, et al. Transitional liver cell tumors (TLCT) in older children and adolescents: a novel group of aggressive hepatic tumors expressing betacatenin. Med Pediatr Oncol 2002; 39: 510-8.
46. Becker G, Schmitt-Graeff A, Ertelt V, et al. CD117 (c-kit) expression in human hepatocellular carcinoma. Clin Oncol (R Coll Radiol) 2007; 19: 204-8.
47. Hanabata M, Ohyanagi H, Saitoh Y, Itoh H. Immunohistochemical study on hepatic tumors - KM01 stains compared with AFP, CEA, CA19-9 and RAS P21. Kobe J Med Sci 1991; 37: 81-96.
48. Tsuji M, Kashihara T, Terada N, Mori H. An immunohistochemical study of hepatic atypical adenomatous hyperplasia, hepatocellular carcinoma, and cholangiocarcinoma with alpha-fetoprotein, carcinoembryonic antigen, CA19-9, epithelial membrane antigen, and cytokeratins 18 and 19. Pathol Int 1999; 49: 310-7.
49. Ng IO, Lai EC, Chan AS, So M.K. Overexpression of p53 in hepatocellular carcinomas: a clinicopathological and prognostic correlation. J Gastroenterol Hepatol 1995; 10: 250-5.
50. Saegusa M, Takano Y, Kishimoto H, et al. Comparative analysis of p53 and c-myc expression and cell proliferation in human hepatocellular carcinomas-an enhanced immunohistochemical approach. J Cancer Res Clin Oncol 1993; 119: 737-44.
51. Wee A, Teh M, Raju G.C. p53 expression in hepatocellular carcinoma in a population in Singapore with endemic hepatitis B virus infection. J Clin Pathol 1995; 48: 236-8.
52. Chen TC, Hsieh LL, Kuo T.T. Absence of p53 gene mutation and infrequent overexpression of p53 protein in hepatoblastoma. J Pathol 1995; 176: 243-7.
53. de La Coste A, Romagnolo B, Billuart P, et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 1998; 95: 8847-51.
54. Legoix P, Bluteau O, Bayer J, et al. Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity. Oncogene 1999; 18: 4044-6.
55. Wei Y, Fabre M, Branchereau S, et al. Activation of betacatenin in epithelial and mesenchymal hepatoblastomas. Oncogene 2000; 19: 498-504.
56. Davila JA, Petersena NJ, Nelson HA, El-Serag H.B. Geographic variation within the United States in the incidence of hepatocellular carcinoma. J Clin Epidemiol 2003; 56: 487-93.
57. Darbari A, Sabin KM, Shapiro CN, Schwarz K.B. Epidemiology of primary hepatic malignancies in U.S. children. Hepatology 2003; 38: 560-6.